BIOMAT Database Logo BIOMAT Database Logo

Adoptive Cell Therapy--Tumor-Infiltrating Lymphocytes, T-Cell Receptors, and Chimeric Antigen Receptors. 2015

Steven A Feldman, and Yasmine Assadipour, and Isaac Kriley, and Stephanie L Goff, and Steven A Rosenberg
Surgery Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD. Electronic address: sar@nih.gov.

UI MeSH Term Description Entries
D009369 Neoplasms New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms. Benign Neoplasm,Cancer,Malignant Neoplasm,Tumor,Tumors,Benign Neoplasms,Malignancy,Malignant Neoplasms,Neoplasia,Neoplasm,Neoplasms, Benign,Cancers,Malignancies,Neoplasias,Neoplasm, Benign,Neoplasm, Malignant,Neoplasms, Malignant
D011946 Receptors, Antigen Molecules on the surface of B- and T-lymphocytes that recognize and combine with specific antigens. Antigen Receptors,Antigen Receptor,Receptor, Antigen
D011948 Receptors, Antigen, T-Cell Molecules on the surface of T-lymphocytes that recognize and combine with antigens. The receptors are non-covalently associated with a complex of several polypeptides collectively called CD3 antigens (CD3 COMPLEX). Recognition of foreign antigen and the major histocompatibility complex is accomplished by a single heterodimeric antigen-receptor structure, composed of either alpha-beta (RECEPTORS, ANTIGEN, T-CELL, ALPHA-BETA) or gamma-delta (RECEPTORS, ANTIGEN, T-CELL, GAMMA-DELTA) chains. Antigen Receptors, T-Cell,T-Cell Receptors,Receptors, T-Cell Antigen,T-Cell Antigen Receptor,T-Cell Receptor,Antigen Receptor, T-Cell,Antigen Receptors, T Cell,Receptor, T-Cell,Receptor, T-Cell Antigen,Receptors, T Cell Antigen,Receptors, T-Cell,T Cell Antigen Receptor,T Cell Receptor,T Cell Receptors,T-Cell Antigen Receptors
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D000951 Antigens, Neoplasm Proteins, glycoprotein, or lipoprotein moieties on surfaces of tumor cells that are usually identified by monoclonal antibodies. Many of these are of either embryonic or viral origin. Neoplasm Antigens,Tumor Antigen,Tumor Antigens,Antigen, Tumor,Antigens, Tumor
D013601 T-Lymphocytes Lymphocytes responsible for cell-mediated immunity. Two types have been identified - cytotoxic (T-LYMPHOCYTES, CYTOTOXIC) and helper T-lymphocytes (T-LYMPHOCYTES, HELPER-INDUCER). They are formed when lymphocytes circulate through the THYMUS GLAND and differentiate to thymocytes. When exposed to an antigen, they divide rapidly and produce large numbers of new T cells sensitized to that antigen. T Cell,T Lymphocyte,T-Cells,Thymus-Dependent Lymphocytes,Cell, T,Cells, T,Lymphocyte, T,Lymphocyte, Thymus-Dependent,Lymphocytes, T,Lymphocytes, Thymus-Dependent,T Cells,T Lymphocytes,T-Cell,T-Lymphocyte,Thymus Dependent Lymphocytes,Thymus-Dependent Lymphocyte
D016219 Immunotherapy, Adoptive Form of adoptive transfer where cells with antitumor activity are transferred to the tumor-bearing host in order to mediate tumor regression. The lymphoid cells commonly used are lymphokine-activated killer (LAK) cells and tumor-infiltrating lymphocytes (TIL). This is usually considered a form of passive immunotherapy. (From DeVita, et al., Cancer, 1993, pp.305-7, 314) Adoptive Cellular Immunotherapy,Adoptive Immunotherapy,CAR T-Cell Therapy,Cellular Immunotherapy, Adoptive,Chimeric Antigen Receptor Therapy,Immunotherapy, Adoptive Cellular,Adoptive Cellular Immunotherapies,Adoptive Immunotherapies,CAR T Cell Therapy,CAR T-Cell Therapies,Cellular Immunotherapies, Adoptive,Immunotherapies, Adoptive,Immunotherapies, Adoptive Cellular,T-Cell Therapies, CAR,T-Cell Therapy, CAR,Therapies, CAR T-Cell,Therapy, CAR T-Cell
D016246 Lymphocytes, Tumor-Infiltrating Lymphocytes that show specificity for autologous tumor cells. Ex vivo isolation and culturing of TIL with interleukin-2, followed by reinfusion into the patient, is one form of adoptive immunotherapy of cancer. Tumor Infiltrating Lymphocyte,Tumor-Derived Activated Cell,Tumor-Derived Activated Cells,Tumor-Infiltrating Lymphocyte,Tumor-Infiltrating Lymphocytes,Activated Cell, Tumor-Derived,Activated Cells, Tumor-Derived,Infiltrating Lymphocyte, Tumor,Infiltrating Lymphocytes, Tumor,Lymphocyte, Tumor Infiltrating,Lymphocyte, Tumor-Infiltrating,Lymphocytes, Tumor Infiltrating,Tumor Derived Activated Cell,Tumor Derived Activated Cells,Tumor Infiltrating Lymphocytes
D064987 Cell- and Tissue-Based Therapy Therapies that involve the TRANSPLANTATION of CELLS or TISSUES developed for the purpose of restoring the function of diseased or dysfunctional cells or tissues. Cell Therapy,Tissue Therapy,Therapy, Cell,Therapy, Tissue,Cell and Tissue Based Therapy

Related Publications

Steven A Feldman, and Yasmine Assadipour, and Isaac Kriley, and Stephanie L Goff, and Steven A Rosenberg
Building better chimeric antigen receptors for adoptive T cell therapy.
April 2010, Current gene therapy,
Steven A Feldman, and Yasmine Assadipour, and Isaac Kriley, and Stephanie L Goff, and Steven A Rosenberg
Making Better Chimeric Antigen Receptors for Adoptive T-cell Therapy.
April 2016, Clinical cancer research : an official journal of the American Association for Cancer Research,
Steven A Feldman, and Yasmine Assadipour, and Isaac Kriley, and Stephanie L Goff, and Steven A Rosenberg
Chimeric antigen receptors for the adoptive T cell therapy of hematologic malignancies.
April 2014, International journal of hematology,
Steven A Feldman, and Yasmine Assadipour, and Isaac Kriley, and Stephanie L Goff, and Steven A Rosenberg
Chimeric antigen receptors for adoptive T cell therapy in acute myeloid leukemia.
August 2017, Journal of hematology & oncology,
Steven A Feldman, and Yasmine Assadipour, and Isaac Kriley, and Stephanie L Goff, and Steven A Rosenberg
Adoptive T Cell Therapies: A Comparison of T Cell Receptors and Chimeric Antigen Receptors.
March 2016, Trends in pharmacological sciences,
Steven A Feldman, and Yasmine Assadipour, and Isaac Kriley, and Stephanie L Goff, and Steven A Rosenberg
Adoptive T-cell therapy of B-cell malignancies: conventional and physiological chimeric antigen receptors.
March 2012, Cancer letters,
Steven A Feldman, and Yasmine Assadipour, and Isaac Kriley, and Stephanie L Goff, and Steven A Rosenberg
Adoptive tumor infiltrating lymphocytes cell therapy for cervical cancer.
November 2022, Human vaccines & immunotherapeutics,
Steven A Feldman, and Yasmine Assadipour, and Isaac Kriley, and Stephanie L Goff, and Steven A Rosenberg
Antigen Identification for Orphan T Cell Receptors Expressed on Tumor-Infiltrating Lymphocytes.
January 2018, Cell,
Steven A Feldman, and Yasmine Assadipour, and Isaac Kriley, and Stephanie L Goff, and Steven A Rosenberg
[Principles of adoptive cell therapy based on "Tumor Infiltrating Lymphocytes"].
May 2016, Revue medicale suisse,
Steven A Feldman, and Yasmine Assadipour, and Isaac Kriley, and Stephanie L Goff, and Steven A Rosenberg
Cytologic Evaluation of Tumor-Infiltrating Lymphocytes for Adoptive Cell Therapy.
March 2020, American journal of clinical pathology,
Copied contents to your clipboard!